Ribonexus (formerly known as Aglaia Therapeutics) is a biotechnology startup developing promising new oncology therapies. The company aims at delivering best- and first- in class drugs that restore sensitivity to current targeted therapies in cancer patients that have become resistant to these treatments. Ribonexus has established a pipeline of small molecules, targeting the initiation of mRNA translation, which the company acquired and developed through Pierre Fabre.
Year of creation: 2021
Line of business: Biopharmaceutics
Institut Curie: Behind the technology and R&D partner
Ribonexus' technology is based on the discovery that many pathways of resistance to current targeted therapies in cancer patients converge on the activation of mRNA translation by the eIF4F complex. EIF4FA, an RNA helicase, is one of the three proteins that compose the eIF4F complex, essential for the cap-dependent translation initiation of many oncogenic proteins. The abnormal activity of this complex, observed in many cancers, leads to the synthesis of proteins involved in tumor growth and metastasis. In addition, the selective translation of cellular mRNAs, controlled by the eIF4F complex, also contributes to the resistance to cancer treatments such as targeted therapies and checkpoint inhibitors. It is the identification of the importance of the mRNA translation regulation process in cancer progression and resistance to treatments that has led to the creation of Aglaia Tx which develops new therapies targeting this process in a cancer context.
Oncology targeted therapies.
Ribonexus aims to advance its preclinical programs in the coming years and select its first innovative program.
More about Ribonexus: